世界の転移性ブドウ膜メラノーマ治療薬市場規模・現状・予測（2021年-2027年）

• 英文タイトル：Global Metastatic Uveal Melanoma Thereapeutics Market Size, Status and Forecast 2021-2027

• レポートコード：QFJ1-5859 • 出版社/出版日：QYResearch / 2021年6月 ※2024年版があります。お問い合わせください。 • レポート形態：英文、PDF、96ページ • 納品方法：Eメール（納期：3日） • 産業分類：医薬品

• 販売価格（消費税別）

Single User	￥577,200 (USD3,900)	▷ お問い合わせ
Multi User	￥865,800 (USD5,850)	▷ お問い合わせ

• ご注文方法：お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法：銀行振込（納品後、ご請求書送付）

---

レポート概要

---

QYResearch社発行の本調査レポートでは、転移性ブドウ膜メラノーマ治療薬の世界市場（2016年～2027年）を対象に調査し、市場動向、主要企業の市場シェア、種類別市場規模（リンゴ酸スニチニブ、硫酸ビンクリスチンリポソーム、LY-2801653、酢酸ソトラスタウリン、その他）、用途別市場規模（病院、クリニック、その他）、主要地域別市場規模（北米、アメリカ、欧州、アジア、日本、中国、韓国、インド、東南アジア、中南米、中東、アフリカ等）、企業情報などをまとめております。 ・市場概要 ・転移性ブドウ膜メラノーマ治療薬の市場動向 ・企業の競争状況、市場シェア ・転移性ブドウ膜メラノーマ治療薬の種類別市場規模と予測2016-2027（リンゴ酸スニチニブ、硫酸ビンクリスチンリポソーム、LY-2801653、酢酸ソトラスタウリン、その他） ・転移性ブドウ膜メラノーマ治療薬の用途別市場規模と予測2016-2027（病院、クリニック、その他） ・転移性ブドウ膜メラノーマ治療薬の北米市場規模2016-2027（アメリカ、カナダ） ・転移性ブドウ膜メラノーマ治療薬の欧州市場規模2016-2027（ドイツ、フランス、イギリス等） ・転移性ブドウ膜メラノーマ治療薬のアジア市場規模2016-2027（日本、中国、韓国、インド、東南アジア等） ・転移性ブドウ膜メラノーマ治療薬の中南米市場規模2016-2027（メキシコ、ブラジル） ・転移性ブドウ膜メラノーマ治療薬の中東・アフリカ市場規模2016-2027（トルコ、サウジアラビア等） ・主要企業情報（AstraZeneca PLC、Eli Lilly and Company、Novartis AG、Pfizer Inc.、Spectrum Pharmaceuticals, Inc.） ・結論

Market Analysis and Insights: Global Metastatic Uveal Melanoma Thereapeutics Market
The global Metastatic Uveal Melanoma Thereapeutics market size is projected to reach US$ XX million by 2027, from US$ XX million in 2020, at a CAGR of XX% during 2021-2027.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Metastatic Uveal Melanoma Thereapeutics market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Metastatic Uveal Melanoma Thereapeutics market in terms of revenue.
On the whole, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Metastatic Uveal Melanoma Thereapeutics market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Metastatic Uveal Melanoma Thereapeutics market.

Global Metastatic Uveal Melanoma Thereapeutics Scope and Market Size
Metastatic Uveal Melanoma Thereapeutics market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global Metastatic Uveal Melanoma Thereapeutics market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application in terms of revenue and forecast for the period 2016-2027.

Segment by Type
Sunitinib Malate
Vincristine Sulfate Liposomal
LY-2801653
Sotrastaurin Acetate
Others

Segment by Application
Hospital
Clinic
Others

By Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

By Company
AstraZeneca PLC
Eli Lilly and Company
Novartis AG
Pfizer Inc.
Spectrum Pharmaceuticals, Inc.

レポート目次

---

1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Metastatic Uveal Melanoma Thereapeutics Market Size Growth Rate by Type: 2016 VS 2021 VS 2027
1.2.2 Sunitinib Malate
1.2.3 Vincristine Sulfate Liposomal
1.2.4 LY-2801653
1.2.5 Sotrastaurin Acetate
1.2.6 Others
1.3 Market by Application
1.3.1 Global Metastatic Uveal Melanoma Thereapeutics Market Share by Application: 2016 VS 2021 VS 2027
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered

2 Global Growth Trends
2.1 Global Metastatic Uveal Melanoma Thereapeutics Market Perspective (2016-2027)
2.2 Metastatic Uveal Melanoma Thereapeutics Growth Trends by Regions
2.2.1 Metastatic Uveal Melanoma Thereapeutics Market Size by Regions: 2016 VS 2021 VS 2027
2.2.2 Metastatic Uveal Melanoma Thereapeutics Historic Market Share by Regions (2016-2021)
2.2.3 Metastatic Uveal Melanoma Thereapeutics Forecasted Market Size by Regions (2022-2027)
2.3 Metastatic Uveal Melanoma Thereapeutics Industry Dynamic
2.3.1 Metastatic Uveal Melanoma Thereapeutics Market Trends
2.3.2 Metastatic Uveal Melanoma Thereapeutics Market Drivers
2.3.3 Metastatic Uveal Melanoma Thereapeutics Market Challenges
2.3.4 Metastatic Uveal Melanoma Thereapeutics Market Restraints

3 Competition Landscape by Key Players
3.1 Global Top Metastatic Uveal Melanoma Thereapeutics Players by Revenue
3.1.1 Global Top Metastatic Uveal Melanoma Thereapeutics Players by Revenue (2016-2021)
3.1.2 Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Players (2016-2021)
3.2 Global Metastatic Uveal Melanoma Thereapeutics Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.3 Players Covered: Ranking by Metastatic Uveal Melanoma Thereapeutics Revenue
3.4 Global Metastatic Uveal Melanoma Thereapeutics Market Concentration Ratio
3.4.1 Global Metastatic Uveal Melanoma Thereapeutics Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Metastatic Uveal Melanoma Thereapeutics Revenue in 2020
3.5 Metastatic Uveal Melanoma Thereapeutics Key Players Head office and Area Served
3.6 Key Players Metastatic Uveal Melanoma Thereapeutics Product Solution and Service
3.7 Date of Enter into Metastatic Uveal Melanoma Thereapeutics Market
3.8 Mergers & Acquisitions, Expansion Plans

4 Metastatic Uveal Melanoma Thereapeutics Breakdown Data by Type
4.1 Global Metastatic Uveal Melanoma Thereapeutics Historic Market Size by Type (2016-2021)
4.2 Global Metastatic Uveal Melanoma Thereapeutics Forecasted Market Size by Type (2022-2027)

5 Metastatic Uveal Melanoma Thereapeutics Breakdown Data by Application
5.1 Global Metastatic Uveal Melanoma Thereapeutics Historic Market Size by Application (2016-2021)
5.2 Global Metastatic Uveal Melanoma Thereapeutics Forecasted Market Size by Application (2022-2027)

6 North America
6.1 North America Metastatic Uveal Melanoma Thereapeutics Market Size (2016-2027)
6.2 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Type
6.2.1 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021)
6.2.2 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2022-2027)
6.2.3 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2027)
6.3 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Application
6.3.1 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2021)
6.3.2 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2022-2027)
6.3.3 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2027)
6.4 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Country
6.4.1 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2016-2021)
6.4.2 North America Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2022-2027)
6.4.3 United States
6.4.4 Canada

7 Europe
7.1 Europe Metastatic Uveal Melanoma Thereapeutics Market Size (2016-2027)
7.2 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Type
7.2.1 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021)
7.2.2 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2022-2027)
7.2.3 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2027)
7.3 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Application
7.3.1 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2021)
7.3.2 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2022-2027)
7.3.3 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2027)
7.4 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Country
7.4.1 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2016-2021)
7.4.2 Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2022-2027)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic

8 Asia-Pacific
8.1 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size (2016-2027)
8.2 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Type
8.2.1 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021)
8.2.2 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2022-2027)
8.2.3 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2027)
8.3 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Application
8.3.1 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2021)
8.3.2 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2022-2027)
8.3.3 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2027)
8.4 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Region
8.4.1 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Region (2016-2021)
8.4.2 Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Region (2022-2027)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia

9 Latin America
9.1 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size (2016-2027)
9.2 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Type
9.2.1 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021)
9.2.2 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2022-2027)
9.2.3 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2027)
9.3 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Application
9.3.1 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2021)
9.3.2 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2022-2027)
9.3.3 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2027)
9.4 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Country
9.4.1 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2016-2021)
9.4.2 Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2022-2027)
9.4.3 Mexico
9.4.4 Brazil

10 Middle East & Africa
10.1 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size (2016-2027)
10.2 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Type
10.2.1 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021)
10.2.2 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2022-2027)
10.2.3 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2027)
10.3 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Application
10.3.1 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2021)
10.3.2 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2022-2027)
10.3.3 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2027)
10.4 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Country
10.4.1 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2016-2021)
10.4.2 Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2022-2027)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE

11 Key Players Profiles
11.1 AstraZeneca PLC
11.1.1 AstraZeneca PLC Company Details
11.1.2 AstraZeneca PLC Business Overview
11.1.3 AstraZeneca PLC Metastatic Uveal Melanoma Thereapeutics Introduction
11.1.4 AstraZeneca PLC Revenue in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021)
11.1.5 AstraZeneca PLC Recent Development
11.2 Eli Lilly and Company
11.2.1 Eli Lilly and Company Company Details
11.2.2 Eli Lilly and Company Business Overview
11.2.3 Eli Lilly and Company Metastatic Uveal Melanoma Thereapeutics Introduction
11.2.4 Eli Lilly and Company Revenue in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021)
11.2.5 Eli Lilly and Company Recent Development
11.3 Novartis AG
11.3.1 Novartis AG Company Details
11.3.2 Novartis AG Business Overview
11.3.3 Novartis AG Metastatic Uveal Melanoma Thereapeutics Introduction
11.3.4 Novartis AG Revenue in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021)
11.3.5 Novartis AG Recent Development
11.4 Pfizer Inc.
11.4.1 Pfizer Inc. Company Details
11.4.2 Pfizer Inc. Business Overview
11.4.3 Pfizer Inc. Metastatic Uveal Melanoma Thereapeutics Introduction
11.4.4 Pfizer Inc. Revenue in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021)
11.4.5 Pfizer Inc. Recent Development
11.5 Spectrum Pharmaceuticals, Inc.
11.5.1 Spectrum Pharmaceuticals, Inc. Company Details
11.5.2 Spectrum Pharmaceuticals, Inc. Business Overview
11.5.3 Spectrum Pharmaceuticals, Inc. Metastatic Uveal Melanoma Thereapeutics Introduction
11.5.4 Spectrum Pharmaceuticals, Inc. Revenue in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021)
11.5.5 Spectrum Pharmaceuticals, Inc. Recent Development

12 Analyst’s Viewpoints/Conclusions

13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

List of Tables
Table 1. Global Metastatic Uveal Melanoma Thereapeutics Market Size Growth Rate by Type (US$ Million):2016 VS 2021 VS 2027
Table 2. Key Players of Sunitinib Malate
Table 3. Key Players of Vincristine Sulfate Liposomal
Table 4. Key Players of LY-2801653
Table 5. Key Players of Sotrastaurin Acetate
Table 6. Key Players of Others
Table 7. Global Metastatic Uveal Melanoma Thereapeutics Market Size Growth by Application (US$ Million): 2016 VS 2021 VS 2027
Table 8. Global Metastatic Uveal Melanoma Thereapeutics Market Size by Regions (US$ Million): 2016 VS 2021 VS 2027
Table 9. Global Metastatic Uveal Melanoma Thereapeutics Market Size by Regions (2016-2021) & (US$ Million)
Table 10. Global Metastatic Uveal Melanoma Thereapeutics Market Share by Regions (2016-2021)
Table 11. Global Metastatic Uveal Melanoma Thereapeutics Forecasted Market Size by Regions (2022-2027) & (US$ Million)
Table 12. Global Metastatic Uveal Melanoma Thereapeutics Market Share by Regions (2022-2027)
Table 13. Metastatic Uveal Melanoma Thereapeutics Market Trends
Table 14. Metastatic Uveal Melanoma Thereapeutics Market Drivers
Table 15. Metastatic Uveal Melanoma Thereapeutics Market Challenges
Table 16. Metastatic Uveal Melanoma Thereapeutics Market Restraints
Table 17. Global Metastatic Uveal Melanoma Thereapeutics Revenue by Players (2016-2021) & (US$ Million)
Table 18. Global Metastatic Uveal Melanoma Thereapeutics Market Share by Players (2016-2021)
Table 19. Global Top Metastatic Uveal Melanoma Thereapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metastatic Uveal Melanoma Thereapeutics as of 2020)
Table 20. Ranking of Global Top Metastatic Uveal Melanoma Thereapeutics Companies by Revenue (US$ Million) in 2020
Table 21. Global 5 Largest Players Market Share by Metastatic Uveal Melanoma Thereapeutics Revenue (CR5 and HHI) & (2016-2021)
Table 22. Key Players Headquarters and Area Served
Table 23. Key Players Metastatic Uveal Melanoma Thereapeutics Product Solution and Service
Table 24. Date of Enter into Metastatic Uveal Melanoma Thereapeutics Market
Table 25. Mergers & Acquisitions, Expansion Plans
Table 26. Global Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021) (US$ Million)
Table 27. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Type (2016-2021)
Table 28. Global Metastatic Uveal Melanoma Thereapeutics Forecasted Market Size by Type (2022-2027) (US$ Million)
Table 29. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Type (2022-2027) & (US$ Million)
Table 30. Global Metastatic Uveal Melanoma Thereapeutics Market Size Share by Application (2016-2021) & (US$ Million)
Table 31. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Application (2016-2021)
Table 32. Global Metastatic Uveal Melanoma Thereapeutics Forecasted Market Size by Application (2022-2027) (US$ Million)
Table 33. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Application (2022-2027) & (US$ Million)
Table 34. North America Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021) (US$ Million)
Table 35. North America Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 36. North America Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2021) (US$ Million)
Table 37. North America Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 38. North America Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 39. North America Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 40. Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021) (US$ Million)
Table 41. Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 42. Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2021) (US$ Million)
Table 43. Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 44. Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 45. Europe Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 46. Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021) (US$ Million)
Table 47. Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 48. Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2021) (US$ Million)
Table 49. Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 50. Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Region (2016-2021) & (US$ Million)
Table 51. Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size by Region (2022-2027) & (US$ Million)
Table 52. Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021) (US$ Million)
Table 53. Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 54. Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2021) (US$ Million)
Table 55. Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 56. Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 57. Latin America Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 58. Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2016-2021) (US$ Million)
Table 59. Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Type (2022-2027) & (US$ Million)
Table 60. Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2016-2021) (US$ Million)
Table 61. Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Application (2022-2027) & (US$ Million)
Table 62. Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2016-2021) & (US$ Million)
Table 63. Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size by Country (2022-2027) & (US$ Million)
Table 64. AstraZeneca PLC Company Details
Table 65. AstraZeneca PLC Business Overview
Table 66. AstraZeneca PLC Metastatic Uveal Melanoma Thereapeutics Product
Table 67. AstraZeneca PLC Revenue in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021) & (US$ Million)
Table 68. AstraZeneca PLC Recent Development
Table 69. Eli Lilly and Company Company Details
Table 70. Eli Lilly and Company Business Overview
Table 71. Eli Lilly and Company Metastatic Uveal Melanoma Thereapeutics Product
Table 72. Eli Lilly and Company Revenue in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021) & (US$ Million)
Table 73. Eli Lilly and Company Recent Development
Table 74. Novartis AG Company Details
Table 75. Novartis AG Business Overview
Table 76. Novartis AG Metastatic Uveal Melanoma Thereapeutics Product
Table 77. Novartis AG Revenue in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021) & (US$ Million)
Table 78. Novartis AG Recent Development
Table 79. Pfizer Inc. Company Details
Table 80. Pfizer Inc. Business Overview
Table 81. Pfizer Inc. Metastatic Uveal Melanoma Thereapeutics Product
Table 82. Pfizer Inc. Revenue in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021) & (US$ Million)
Table 83. Pfizer Inc. Recent Development
Table 84. Spectrum Pharmaceuticals, Inc. Company Details
Table 85. Spectrum Pharmaceuticals, Inc. Business Overview
Table 86. Spectrum Pharmaceuticals, Inc. Metastatic Uveal Melanoma Thereapeutics Product
Table 87. Spectrum Pharmaceuticals, Inc. Revenue in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021) & (US$ Million)
Table 88. Spectrum Pharmaceuticals, Inc. Recent Development
Table 89. Research Programs/Design for This Report
Table 90. Key Data Information from Secondary Sources
Table 91. Key Data Information from Primary Sources
List of Figures
Figure 1. Global Metastatic Uveal Melanoma Thereapeutics Market Share by Type: 2020 VS 2027
Figure 2. Sunitinib Malate Features
Figure 3. Vincristine Sulfate Liposomal Features
Figure 4. LY-2801653 Features
Figure 5. Sotrastaurin Acetate Features
Figure 6. Others Features
Figure 7. Global Metastatic Uveal Melanoma Thereapeutics Market Share by Application: 2020 VS 2027
Figure 8. Hospital Case Studies
Figure 9. Clinic Case Studies
Figure 10. Others Case Studies
Figure 11. Metastatic Uveal Melanoma Thereapeutics Report Years Considered
Figure 12. Global Metastatic Uveal Melanoma Thereapeutics Market Size (US$ Million), Year-over-Year: 2016-2027
Figure 13. Global Metastatic Uveal Melanoma Thereapeutics Market Size (US$ Million), 2016 VS 2021 VS 2027
Figure 14. Global Metastatic Uveal Melanoma Thereapeutics Market Share by Regions: 2020 VS 2027
Figure 15. Global Metastatic Uveal Melanoma Thereapeutics Market Share by Regions (2022-2027)
Figure 16. Global Metastatic Uveal Melanoma Thereapeutics Market Share by Players in 2020
Figure 17. Global Top Metastatic Uveal Melanoma Thereapeutics Players by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Metastatic Uveal Melanoma Thereapeutics as of 2020
Figure 18. The Top 10 and 5 Players Market Share by Metastatic Uveal Melanoma Thereapeutics Revenue in 2020
Figure 19. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Type (2016-2021)
Figure 20. Global Metastatic Uveal Melanoma Thereapeutics Revenue Market Share by Type (2022-2027)
Figure 21. North America Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 22. North America Metastatic Uveal Melanoma Thereapeutics Market Share by Type (2016-2027)
Figure 23. North America Metastatic Uveal Melanoma Thereapeutics Market Share by Application (2016-2027)
Figure 24. North America Metastatic Uveal Melanoma Thereapeutics Market Share by Country (2016-2027)
Figure 25. United States Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 26. Canada Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 27. Europe Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 28. Europe Metastatic Uveal Melanoma Thereapeutics Market Share by Type (2016-2027)
Figure 29. Europe Metastatic Uveal Melanoma Thereapeutics Market Share by Application (2016-2027)
Figure 30. Europe Metastatic Uveal Melanoma Thereapeutics Market Share by Country (2016-2027)
Figure 31. Germany Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 32. France Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 33. U.K. Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 34. Italy Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 35. Russia Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 36. Nordic Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 37. Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 38. Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Share by Type (2016-2027)
Figure 39. Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Share by Application (2016-2027)
Figure 40. Asia-Pacific Metastatic Uveal Melanoma Thereapeutics Market Share by Region (2016-2027)
Figure 41. China Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 42. Japan Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 43. South Korea Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 44. Southeast Asia Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 45. India Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 46. Australia Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 47. Latin America Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 48. Latin America Metastatic Uveal Melanoma Thereapeutics Market Share by Type (2016-2027)
Figure 49. Latin America Metastatic Uveal Melanoma Thereapeutics Market Share by Application (2016-2027)
Figure 50. Latin America Metastatic Uveal Melanoma Thereapeutics Market Share by Country (2016-2027)
Figure 51. Mexico Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 52. Brazil Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 53. Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 54. Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Share by Type (2016-2027)
Figure 55. Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Share by Application (2016-2027)
Figure 56. Middle East & Africa Metastatic Uveal Melanoma Thereapeutics Market Share by Country (2016-2027)
Figure 57. Turkey Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 58. Saudi Arabia Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 59. UAE Metastatic Uveal Melanoma Thereapeutics Market Size YoY Growth (2016-2027) & (US$ Million)
Figure 60. AstraZeneca PLC Revenue Growth Rate in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021)
Figure 61. Eli Lilly and Company Revenue Growth Rate in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021)
Figure 62. Novartis AG Revenue Growth Rate in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021)
Figure 63. Pfizer Inc. Revenue Growth Rate in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021)
Figure 64. Spectrum Pharmaceuticals, Inc. Revenue Growth Rate in Metastatic Uveal Melanoma Thereapeutics Business (2016-2021)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

---